Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, August 29, 2017

Ecstasy Was Just Labelled a 'Breakthrough Therapy' For PTSD by The FDA

Does your doctor even know about the 23% chance of stroke survivors getting PTSD? And what is s/he doing about it? There are also some states allowing medical marijuana for PTSD. I'm sure they won't believe or allow use for stroke related PTSD.

Ecstasy Was Just Labelled a 'Breakthrough Therapy' For PTSD by The FDA 


KYREE LEARY, FUTURISM
29 AUG 2017

The US Food and Drug Administration (FDA) has determined that 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, is a 'breakthrough therapy' in the treatment of post-traumatic stress disorder (PTSD).
Thanks to this designation, the drug could have a faster path to pharmaceutical approval.
The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the FDA's ruling last week, revealing that they can now move forward on two of their upcoming 'Phase 3' trials.
The goal of these trials is to determine how effectively the drug can be used to treat those suffering from PTSD. The trials will include 200 to 300 participants, and the first trial will begin to accept subjects in 2018.
"For the first time ever, psychedelic-assisted psychotherapy will be evaluated in Phase 3 trials for possible prescription use, with MDMA-assisted psychotherapy for PTSD leading the way," said Rick Doblin, Founder and Executive Director of MAPS.
The trials will be held in the U.S., Canada, and Israel, and MAPS plans to open talks with the European Medicines Agency in the hopes of expanding testing to include Europe. For now, the focus is on securing the funding they require.
According to Science, the organisation is still in the process of raising money for the trials, and thus far, they've only managed to secure US$13 million, about half of their goal.
Since 1986, MAPS has been conducting MDMA trials in the hopes of proving the drug's therapeutic value. Following the 2011 release of a small study in the US, the drug has gained traction as a potential treatment for PTSD.

No comments:

Post a Comment